Dasatinib treatment for Philadelphia chromosome-positive Leukemias: practical considerations

Date

2009

Authors

Khoury, H.
Guilhot, F.
Hughes, T.
Kim, D.
Cortes, J.

Editors

Advisors

Journal Title

Journal ISSN

Volume Title

Type:

Journal article

Citation

Cancer, 2009; 115(7):1381-1394

Statement of Responsibility

Hanna Jean Khoury, François Guilhot, Timothy P. Hughes, Dong-Wook Kim and Jorge E. Cortes

Conference Name

Abstract

Dasatinib is a highly potent Bcr-Abl inhibitor that is approved for the treatment of imatinib-resistant or -intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. Across a series of phase 2 and 3 trials, dasatinib was associated with durable treatment responses in all phases of the disease and was well tolerated. For this article, the authors reviewed available information on specific side effects associated with the use of dasatinib. On the basis of more than 2 years' experience of dasatinib treatment during clinical trials, they provide practical recommendations for side-effect management.

School/Discipline

Dissertation Note

Provenance

Description

Access Status

Rights

Copyright © 2009 American Cancer Society

License

Grant ID

Call number

Persistent link to this record